Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486862 | 0.85 | ALDH1A1 (0.46) | PDE4DSMPD1MEN1KMT2AC5AR1 | |
| SCHEMBL6490615 | 0.81 | IDO1 (0.47) | — | |
| SCHEMBL6477614 | 0.79 | FFAR1 (0.47) | SMN1; SMN2LMNAMEN1KMT2AANO1 | |
| SCHEMBL6474650 | 0.76 | PDE4D (0.45) | SMN1; SMN2PDE4DLMNASMPD1KMT2A | |
| SCHEMBL6476541 | 0.75 | MCL1 (0.53) | SMN1; SMN2LMNAMEN1KMT2AFDPS | |
| SCHEMBL6476729 | 0.68 | CYSLTR2 (0.40) | — | |
| SCHEMBL4091879 | 0.68 | CNR1 (0.71) | CNR1 | |
| SCHEMBL18129645 | 0.66 | MTNR1B (0.54) | MEN1KMT2A | |
| SCHEMBL791693 | 0.66 | NPC1 (0.50) | PDE4DC5AR1CNR1 | |
| SCHEMBL1518832 | 0.65 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933322-B2 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2005-08-23 | — | — | US | disclosed |
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | INSR, GPR119, SLC5A1 | SMN1; SMN2 1928/4885PDE4D 2235/4885LMNA 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.